Last update Dec. 3, 2022
Very Low Risk
We do not have alternatives for Buserelin since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Buserelin is also known as
Buserelin in other languages or writings:
Buserelin belongs to this group or family:
|T½||1.3 (1 - 2)||hours|
|Theoretical Dose||0.00003 - 0.0013||mg/Kg/d|
|Relative Dose||0.3 - 13||%|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A synthetic decapeptide, similar to gonadorelin, analogue of natural luteinizing hormone releasing hormone (LHRH). Indicated in in vitro fertilization treatments before stimulation with exogenous gonadotropins for ovarian stimulation. Subcutaneous administration daily for 15 to 21 days. It is also used in carcinomas of the prostate and endometriosis.
Buserelin, administered by intranasal inhalation, is excreted in human milk in negligible or undetectable amounts and does not cause hormonal alterations in infants breastfed by mothers taking it (Dewart 1987), nor alterations in lactation. (Fraser 1989)
Its high molecular weight would explain this tiny passage into breast milk.
Due to its protein nature, it is inactivated in the gastrointestinal tract (Van Leusden 1994, Fraser 1993), not being absorbed (practically zero oral bioavailability), which hinders its transfer into the infant's plasma from breastmilk, except in premature infants and the immediate neonatal period, when there may be greater intestinal permeability.
Increased prolactin has been observed in women treated with gonadorelin analogues and gonadotropins (Cavagna 2005, Kamel 1994, Meldrum 1992), although the findings are not consistent. (Chantilis 1995)
See below the information of this related product: